TrialsgrambetaRCTs are beautiful

Genitourinary cancers

Triplet therapy in mHSPC, immune-combination therapy in RCC, ADC-immunotherapy in urothelial and PSMA radioligand therapy.

Trials
4
Years
2015–2024
Sort
  • 2024EV-302 / KEYNOTE-A39⁠Urothelial 1LIn 886 patients with untreated advanced urothelial carcinoma, enfortumab vedotin + pembrolizumab improved progression-free and overall survival compared with platinum-based chemotherapy.HR 0.47Read →
  • 2021VISION⁠mCRPC PSMA-RLTIn 831 patients with PSMA-positive mCRPC after androgen-receptor signalling inhibition and taxane chemotherapy, 177Lu-PSMA-617 + standard care improved radiographic PFS and overall survival compared with standard care alone.HR 0.62Read →
  • 2018CheckMate-214⁠Advanced RCCIn 1,096 patients with untreated advanced clear-cell renal cell carcinoma, nivolumab + ipilimumab improved overall survival in intermediate/poor-risk patients compared with sunitinib.HR 0.63Read →
  • 2015CHAARTED⁠mHSPCIn 790 patients with metastatic hormone-sensitive prostate cancer, ADT + docetaxel improved overall survival compared with ADT alone.HR 0.61Read →